Dyadic International (DYAI)

• Market cap: $51.8M
• 1 day: -8.38%
• 5 days: 10.06%
• 1 month: 17.45%
• 3 months: 40.00%
• 6 months: -3.31%
• Year to date: 10.06%
• 1 year: 12.18%
• 5 years: -66.28%
• 10 years: -48.53%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

Employees: 7

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

0.1% more ownership

Funds ownership: 16.11% [Q2] → 16.21% (+0.1%) [Q3]

10% less funds holding

Funds holding: 39 [Q2] → 35 (-4) [Q3]

29% less capital invested

Capital invested by funds: $6.97M [Q2] → $4.98M (-$2M) [Q3]

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $6 243% upside
• Avg. target: $6 243% upside
• High target: $6 243% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Vernon Bernardino 32% 1-year accuracy 19 / 59 met price target

243% upside $6

Buy Reiterated

14 Nov 2024